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1. INTRODUCTION 
Direct compression is the most efficient process used in tablet manufacturing because it is 
the fastest, simplest, and least expensive tablet-compression procedure. However, although this 
technique seems quite simple, it requires that different properties of drug materials (free flow and 
plastic behaviour) should be manifested simultaneously. Many drugs do not exhibit these 
properties: they have poor flowability and compressibility. For tablet making from the latter 
materials, possible solutions may be as follows: 
- the use of wet granulation and agglomeration [1] (if this is possible with regard to the 
drug stability), 
- the use of direct tablet making with "good" excipients which promote direct 
compression (though this might not be favourable in terms of powder flow), 
- the use of direct pressing with spherical agglomerates of drug crystals with good 
flowability and compressibility properties. 
The third of these possibilities recently came into the forefront of interest because the 
habit of the particles (form, size, particle size distribution, surface, etc.) can be changed by the 
crystallization process. The spherical crystallization (agglomeration) technique has recently 
received great attention and gained considerable importance in the pharmaceutical field. 
The particle diameter of drug materials produced by spherical crystallization is about 
300-500 pm and their form is more or less spherical. The agglomerates exhibit very good flow, 
high bulk density and high compressibility. 
Consequently, the spherical crystallization process allows raw materials with 
unfavourable technological properties to be utilized for direct tablet making. 
2. LITERATURE 
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2.1. Crystallization (in general) 
Crystallization is one of the oldest and most important operations. It is widely used in the 
chemical and pharmaceutical industries for purification, separation and/or production, yielding 
good-quality crystals. The number of phases in a crystallization process may be two, three or 
more than three. Crystallization can be carried out from a solution, vapour or melt [2-5]. It is 
well known that the morphology of crystals depends strongly on the crystal growth conditions. 
The influence of the rates of the nucleation and crystal growth processes (temperature, stirring, 
method, additives, etc.) is very important, as is demonstrated by many examples in the literature 
[6-9]. 
The simple solubility diagram provides a limited amount of information. The phase 
diagram graphically presents, in two or three dimensions, a more complete picture of the 
equilibria between various phases of the system over wide ranges of temperature, pressure and 
concentration. The Gibbs phase rule relates the numbers of components, C, phases, P, and 
degrees of freedom, F, of a system at equilibrium by means of the simple relation 
P+F=C+2 
The process of nucleation involves the formation of new crystals in a crystallizing 
environment. The supersaturated state of a solution is a prerequisite, but not a sufficient cause for 
a system to begin to crystallize, since a large number of minute entities known as centres of 
crystallization, embryos, or seeds first exist in the solution. The generation of a new crystalline 
phase from solution under conditions where a free energy barrier exists is a process of nucleation 
from solution. 
The nucleation rate by a primary homogeneous nucleation mechanism may be expressed by 
J=exp(-AG/kT) 
where 
J= nucleation rate, 
AG= free energy between a small particle of solid solute and the solute in solution, 
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k= rate constant, and 
T= temperature. 
Various theories have been evolved to describe the crystal growth processes taking place 
at different magnification levels, spanning from the atomic to the macroscopic scale, and to 
develop growth rate expressions theoretically. For engineering purposes in crystallizer design 
and assessment, the simple empirical powder-law relationship expressing the specific rate of 
mass deposition is given by 
R=(l/ A t ) (dW/dt) = K C A C 8 
where 
R= overall growth rate based on mass deposition, 
AT= total crystal surface area, 
W= mass of crystals, 
t= time, 
kG = growth rate constant, 
AC?= concentration of crystal. 
In general, the overall growth rate constant (kG) depends on the temperature, the crystal size, the 
hydrodynamic situation and the presence of impurities [10-13]. 
Types of crystallization equipment 
cooling crystallizer, 
vacuum crystallizer, 
crystallizing boiler, 
reactor crystallizer, and 
fluid bed crystallizer. 
Methods of crystallization 
salting-out precipitation, 
cooling crystallization, 
crystallization from the melt, etc. [14-17]. 
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2.2. Spherical crystallization 
One crystal growth process is the development of crystal agglomerates by spherical 
crystallization. In the pharmaceutical field, Kawashima et al. [18] gave an impulse to this 
research in the early 1980s. Spherical crystallization was defined by Kawashima as "an 
agglomeration technique that transforms crystals directly into a compacted spherical form during 
the crystallization process". 
A few methods are to be found in the literature. The typical spherical crystallization 
process employs three solvents: one is the substance dissolution medium; another is the medium 
which partially dissolves the substance; and the third is the wetting solvent for the substance. In 
the three-solvent system, the dissolved drug material is carried in emulsion drops (Fig. 1). Due to 
the effect of diffusion, the molecules of a good solvent (e.g. ethanol) leave the emulsion drops 
and enter the poor-solvent phase (e.g. water) through the emulsion film. The drops become 
oversaturated with respect to the drug material, and in situ seed formation starts at a given 
temperature, followed by crystal formation. The emulsion drops determine the size of crystal 
agglomerates. Therefore, the nature and the ratio of the solvents, the temperature, and the rates of 
cooling and stirring in the same way determine the quality of the 
product. 
with wetting solvent 
Fig. 1: Typical spherical crystallization process 
Traditional crystallization processes (salting-out precipitation, cooling crystallization, 
crystallization from the melt, etc.) can also be used to produce spherical crystal agglomerates. 
The traditional crystallization process is carried out by controlling the physical and chemical 
properties. It may be called a non-typical spherical crystallization process. 
good solvent left the 
emulsion drops 
formation of crystal 
agglomerates 
8 
The residual solvent content in crystal agglomerates is a very important question [19]. 
Many drugs which do not have suitable technological properties have been successfully 
transformed into spherical agglomerates with good flowability and compressibility during 
manufacturing, because the physicochemical properties of the pharmaceutical crystals are 
dramatically improved for the pharmaceutical processes, e.g. mixing, filling and direct tabletting 
(e.g. salicylic acid [20,21], enoxacin [22], DL-methionine [23], phenytoin [24], ferrous sulfate 
[25], propyphenazone [26], ketoprofen [27], meprobamate [28], acetylsalicylic acid [29], 
ibuprofen [30-33], 3-nitro-l,2,4,-triazol-5-one [34], acebutolol hydrochloride [35], paracetamol 
[36-38] and theophyllin [39,40] (Figs 2 and 3). 
Et hanoI (%) 50A0 
60 50 Chtoroform <%) 
D i a g r a m s h o w i n g the solubil i ty of 
ch lo ro fo rm in t h e e t h a n o l - w a t c r mix tu re . 
Ch lo ro fo rm was m i sc i b l e (A/) in the region 
above the solid line a n d immisc ib le (/) in the 
region be low the sol id l ine. A c c e p t a b l e spher -
ical c rys ta l l i za t ion o c c u r r e d in the s h a d e d 
region. 
Fig. 2: Spherical agglomerates (a) and the commercial product (b) of the salicylic acid 
[18] 
i 1 = 33 (xm i 1 = 1 0 0 (iin 
Fig. 3: Spherical agglomerates of the paracetamol [36] 
Other materials are currently awaiting such transformation, to make them suitable for 
direct compression. 
i • ' 'Tv c 
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2.3. Direct tabletting 
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Direct compression is a modern method in tablet manufacturing. Many processing steps 
(granulation, drying, etc.) are eliminated in direct compression; additionally, wet technology can 
not be used with sensitive agents (e.g. in effervescent or chewable tablet-making) [41]. However, 
the use of this technique, which seems quite simple, depends on 
=> the crystal form and surface, 
=> the particle size and the particle size distribution of the materials and, in connection with this, 
=> the flowability of the crystals, consistent with the production rates of modern compression 
technologies, 
=> the bulk density of the powder, in order to feed the correct amount of drug into a die cavity, 
and 
=> the compressibility of the material. 
Some drug crystals exhibit appropriate such properties, but many materials have very 
poor flowability and compressibility [42]. Previously, only the use of excipients with good 
technological properties made it possible to tablet such drugs, so these vehicles were developed 
[43-53]. 
The most advantageous crystals for direct tabletting are compacted, nearly spherical and 
shapeless and their particle size distribution is monodisperse. These good macromorphological 
attributes ensure suitable flowability and compressibility [54-65]. 
The flowability of materials (according to the Carr index) may be classified as excellent, 
good, fair to passable, poor, very poor, or very very poor [66]. 
It may be necessary to perform compressibility studies, and to calculate the Stamm-
Mathis [67] or Emschermann plasticity [68] in order to determine tablettability [69]. The results 
allow the classification of materials from the aspect of direct tablet making. 
2.4. Chewable tablets 
Chewable tablets are becoming increasingly popular in the pharmaceutical and food 
industries. The special advantages of this class of tablets include their convenience and popular 
acceptance (e.g. for young children and some geriatric persons), and in certain cases chewable 
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tablets are more advantageous than effervescent tablets for the supply of vitamins and minerals 
(e.g. there is no dissolving). 
These tablets exhibit good bioavailability and rapid absorption [70]. The pleasant sweet 
taste and mouth-feel are very important attributes, but chewable tablets have to meet other 
requirements too (e.g. stability, efficiency and quality of tablet form). In general, gritty or 
gummy textures are undesirable, whereas a soothing and cooling sensation with a smooth texture 
is preferred. 
Chewable tablets are produced by direct tablet pressing because they usually contain 
vitamins, minerals, antacids and rarely other drugs (anodynes, antifebriles or antiepileptica) 
which are sensitive to moisture [71-78]. A good direct compression vehicle for chewable tablets 
must also possess a pleasant sweet taste and a good mouth-feel. To achieve this desired taste with 
good direct compression qualities, the monosaccharide and disaccharide classes of sugars or 
polyols are used. The monosaccharides and disaccharides include sucrose, dextrose, fructose and 
lactose, while mannitol, sorbitol, xylitol and maltitol are of the polyol type. 
Establishment of chewable tablets 
1. First, the formulator should determine the attributes of the pure drug: the basic taste, inherent 
flavour and aroma, mouth-feel and after-effects. 
2. The second step is an attempt to mask the taste (without flavouring) by various 
physicochemical techniques such as microencapsulation, adsorption, ion-exchange, spray 
congealing, or the formation of different salts or derivatives. If the dose is low or the taste of 
the drug is not too unpleasant, this step may be unnecessary. 
3. Third, it is necessary to choose a chewable vehicle and other adjuvants (e.g. binders, 
lubricants and colours) and their quantities in order to achieve optimum flow and 
compressibility. 
4. The final step is to flavour the chewable tablets. It is necessary to consider two or three 
alternative flavours or masking methods and to choose the best among them. 
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3. AIMS 
The topicality of the topic is given by the changed qualitative requirements in respect of 
the drug materials. The technological parameters come into prominence, which can result in a 
more economical process for the development of the solid dosage forms. The present research 
work relates to the improvement of the technological parameters of drug materials via the 
crystallization process, the quality of the products and the formulation of chewable tablets with 
control and developed active agents. 
This work had three aims, as follows: 
•=!> Improvement of the technological properties (particle size and form, flowability, 
compressibility, etc.) of active drugs (acetylsalicylic acid (ASA), magnesium aspartate(Mgasp)) 
by typical and non-typical spherical crystallization in order to make them suitable for direct 
tablet making. 
•=!> Quality control of the products: 
-determination of macro- and micromorphological parameters (particle form, size, particle size 
distribution, specific surface and micropore volume); 
-thermoanalytical investigations (TGA, DTA and DSC); 
-atomicabsorption analysis (determination of magnesium content); 
-recording of diffuse reflectance spectra (NIR); 
-investigation of technological properties (flowability, rearrangement, cohesivity and 
compressibility). 
•=!> Development and investigation of chewable tablets containing Mgasp and different 
polyols. 
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4. MATERIALS AND METHODS 
4.1. Materials 
4.1.1. Commercial acetylsalicylic acid (ASA) 
(C9Hg04=180.2) (Ph. Eur. 4) 
Commercial ASA crystals are colourless or white, odourless or almost odourless 
tetragonal and prism-shaped, with different sizes and particle size distributions. ASA is stable in 
dry air, but gradually hydrolyses in contact with moisture to give acetic acid and salicylic acid 
(SA). The BP solubilities: slightly soluble in water, freely soluble in alcohol, soluble in 
chloroform and in ether. 
ASA crystals exhibit poor flow due to the crystal habit and the electrostatic charge. Since 
ASA crystals can be compressed to tablets (e.g. effervescent or chewable) only via direct tablet-
making methods (stability!), the good flowability, cohesivity and tablettability of the crystals are 
very important. 
ASA is used to treat pain, fever, inflammation and the prevention of myocardial 
infarction and stroke. The main adverse effects associated with the use of ASA are gastro-
intestinal. 
4.1.2. ASA developed by spherical crystallization (ASA1, ASA2 and ASA3) 
ASA crystals were developed by means of non-typical and typical spherical 
crystallization processes with different solvent mixtures. Three different samples were produced 
by variation of the experimental conditions. The experiments were carried out in a mechanically 
stirred tank with a volume of 500 ml. A Julabo thermostat with computer control was used for 
the cooling process. A non-typical spherical crystallization process was used for the samples 
ASA1 and ASA2, whereas AS A3 was developed by a typical spherical crystallization procedure. 
ASAI: 160 g of ASA was dissolved in 500 ml of ethanol (40% v/v) at 60 °C, followed by 
cooling at 1 °C/min to 20 °C with stirring (200 r.p.m.). 
ASA2: 160 g of ASA was dissolved in 500 ml of ethanol (40% v/v) at 60 °C, followed by 
cooling at 0.5 °C/min to 20 °C with stirring (200 r.p.m.). 
AS A3: 121.6 g of ASA was dissolved in 225 ml of ethanol (40% v/v) at 50 °C, and a carbon 
tetrachloride - water mixture (4% w/v) was added, followed by cooling at 0.6 °C/min to 20 °C 
with stirring (200 r.p.m.) The ASA3 crystallization process can be followed in Fig. 4. 
1 3 
[Min] 
Figure 4: Cooling curves of crystallization process of ASA3 
A1 cooling curve of equipment; 
B/ cooling curve of solution 
1/ dissolution of ASA crystals adding of carbon tetrachloride-water mixture (4%w/v) to 
the solution; 
2/ appearance of ASA crystals 
4.1.3. Commercial magnesium aspartate (Mgasp) 
(magnesium aminosuccinate tetrahydrate, C8H12MgN208-4H20=360.6) 
Mgasp is a white, odourless and tasteless powder. The edges of the crystals are round; the 
surface is smooth. The particle size of the crystals is very small, so this material is unsuitable for 
direct pressing. 
It is well known that magnesium is an important element for the human organism [79-
85], A mixture of equal parts of potassium aspartate and Mgasp has been claimed to be of value 
in the management of fatigue, heart conditions and liver disorders, but the claims are not 
supported by adequate evidence. Various quantities of magnesium enter the organism with the 
food, but in many cases care should be taken to guarantee the supply (e.g. in children, pregnant 
women and elderly people). The recommended daily intake of magnesium as a food supplement 
is from 50 to 450 mg, depending on the age and the geographical location. The level was 
maximized by the WHO as up 200 to 300 mg per day. 
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4.1.4. Mgasp developed by spherical crystallization (Mgaspl, Mgasp2 and Mgasp3) 
The spherical crystal agglomeration of Mgasp was carried out by salting-out combined 
with cooling (Fig. 5). The samples were produced under different experimental conditions. The 
experiments were carried out in a mechanically stirred tank with a volume of 1000 ml. A Julabo 
thermostat with computer control (Julabo Labortechnik GmbH, Seelbach, Germany) was used 
for the cooling process. 500 ml of 15-25 wt% Mgasp solution was placed in the crystallizer tank. 
The solvent was water. The salting-out agent was methanol (25-100%, in relation to the 
measured solution). 
Traditional mechanical stirring crystallization was used for Mgaspl and Mgasp2 (Fig. 5). 
The stirring rate was higher for Mgaspl (100 rpm) than for Mgasp2 (60 rpm). The methanol 
feeding rate was constant (0.36 1/h). The temperature interval was 90-10 °C. The crystallization 
processes of Mgaspl and Mgasp2 differed further in cooling rate. For Mgaspl, slower initial 
cooling (0.3 °C/min) was used than for Mgasp2 (0.7 °C/min). The duration of the crystallization 
Fig. 5: Schematic representation of the spherical agglomeration of Mgasp 
Mgasp3 was prepared in a mechanically stirred tank (800 ml) with an external circulation 
loop (recirculation process). Methanol was added to the external loop. The initial concentrations, 
the stirring rate and the temperature interval were the same as for Mgaspl. The mother liquor 
recirculation rate (20 1/h), the methanol feeding rate (0.3 1/h) and the cooling rate (0.5 °C/min) 
were different. The duration of the crystallization process was 190 min. After the precipitation of 
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crystal agglomerates, the solvent mixture (water - methanol) was removed by filtration in 
vacuum (100 mbar). The concentration of Mgasp in the filtrates was 2-2.5 wt%. The 
agglomerates were washed with cold methanol (0 °C), and subsequently dried at 50 °C to mass 
constancy. The products were finally kept in a dark and dry place. The parameters of the 
crystallization processes are summarized in Table 1. 
Table 1: Conditions of crystallization of Mgasp 
Mgaspl Mgasp2 Mgasp3 
traditional mechanical 
stirring 
traditional mechanical 
stirring with recirculation 
of mother liquor 
Stirring rate (r.p.m.) 100 60 100 
Feeding rate of salting-out 
agent (methanol) (1/h) 
0.36 0.36 0.30 
Temperature interval (°C) 90-10 90-10 
Cooling rate (°C/min) 0.3 0.7 0.5 
Process time (min) 140-260 190 
Mother liquor recirc. rate (1/h) - 20 
Filtration in vacuum (mbar) 100 100 100 
Washing (cold methanol) (°C) 0 0 0 
Drying (°C) 50 50 50 
4.1.5. Excipients 
Polvols 
Polyols (e.g. sorbitol, mannitol and xylitol) are widely used materials with a pleasant 
sweet taste, and no aftertaste. They have many applications in the pharmaceutical, food and 
cosmetic industries [86-93]. Polyols are not metabolized by oral bacteria and are therefore not 
acidogenic or cariogenic. 
Polyols are polyhydric alcohols and closely related to sugars, but with the sugar aldehyde 
or ketone group replaced by a hydroxy group. The hydroxy group is less reactive than the sugar 
aldehyde or ketone group. The polyols have low hygroscopicity (especially mannitol), stabilize 
the moisture content and improve storage. They are very stable to heat and melt without 
decomposition. The polyols induce very low glycaemia, and are suitable for diabetics. These 
materials are completely safe for use in foods. The acceptable daily intake for all polyols is given 
as "not specified" by the JECFA (Joint FAO/WHO Expert Committee on Food Additives). The 
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relative sweetness of these materials is compared with that of sucrose: sucrose: 1; sorbitol: 0.7; 
mannitol: 0.4. The sweetness of xylitol is equivalent to that of sucrose [94]. They can usually be 
used as filler and binder excipients in chewable tablets. 
During the formulation of chewable tablets with Mgasp, the following polyols were used: 
Neosorb P 20/60 (D-sorbitol, Roquette, Lestrem, France) 
A white, crystalline powder with a sweet taste. D-Sorbitol is produced by the catalytic 
hydrogenation of D-glucose. D-Sorbitol contains six alcohol groups, i.e.it is a hexitol. 
Karion Instant Pharma (D-sorbitol, Merck, Darmstadt, Germany) 
A white, granulated powder with a sweet taste and a low mass by volume. 
Xylisorb 700 (xylitol, Roquette, Lestrem, France) 
A white, crystalline powder with a sweet taste. Xylisorb is produced by the catalytic 
hydrogenation of xylose. Xylitol, containing five alcohol groups, is a pentitol. 
Pearlitol SD 200 (D-mannitol, Roquette, Lestrem, France) 
A white, crystalline powder with a sweet taste, produced by the catalytic hydrogenation 
of D-fructose. Mannitol is a hexitol, having six alcohol groups. 
Pearlitol 400 DC (D-mannitol, Roquette, Lestrem, France) 
A white, crystalline powder with a sweet taste. 
Magnesium stearate (Ph. Eur. 4) 
This is a white, sticky, fine and light powder. It is tasteless and odourless. It is insoluble 
in water, alcohol and diethyl ether. It is used in tablet manufacturing as an antiadhesive 
substance, in 0.1-1%. 
4.2. Methods 
Particle size analysis and roundness 
The particle sizes of the materials were measured by sieving (DIN sieve, German 
Standard). (100 g of material was sieved with an Erweka vibration sieve (Erweka Apparatebau 
GmbH, Heusenstamm, Germany). The vibration rate was 200 strokes/min and the sieving time 
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was 10 min. The powder fractions retained by the individual sieves were measured and expressed 
in mass percentages.) 
Determinations of particle size (length, breadth and roundness) were carried out with a 
Laborlux S light microscope and a Quantimet 500 MC (Q 500 MC) image processing and 
analysis system (LEICA Cambridge, Ltd., UK). 
Roundness is a shape factor that provides information on the circularity of particles. It is 
calculated by software according to the following formula: 
roundness=perimeter2/47farea-1.064 
The perimeter was calculated from the horizontal and vertical projections, with an allowance for 
the number of comers. An adjustment factor of 1.064 corrected the perimeter for the effect of the 
comers produced by digitization of the image. When the roundness value is close to one, the 
particles are nearly spherical. 
Scanning electronmicroscopic investigations 
The crystals were observed with a scanning electron microscope (Hitachi Scientific 
Instrument, Ltd., Tokyo, Japan). A Polaron sputter coating apparatus (Polaron Equipment, Ltd., 
Greenhill, UK) was applied to induce electric conductivity on the surface of the sample. The 
surfaces of the Mgasp crystals were treated with gold for 60 s (coating thickness: 18 nm). 
Micromorphological investigations: BET and BJH methods 
The specific surfaces and micropore volumes of samples were determined with 
Micromeritics ASA 2000 equipment (Instrument Corp., Norcross, Ga., USA)) from the data (20 
points each) of nitrogen adsorption and desorption isotherms at the boiling point of liquid 
nitrogen at atmospheric pressure (-196 °C). The specific surface was calculated, in the range of 
validity of the BET -isotherm [95], from the slope and intercept of a line characterized by 5 
measuring points. The samples (1.5-2.0 g) were degassed at 60 °C by vacuum up to an absolute 
pressure of 1 Pa. After degassing, the samples were weighed again and the morphological 
parameters were calculated for the "surface-cleaned" mass of samples. The micropore volumes 
were calculated via the BJH method [96]. The investigations were repeated 3 times. 
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Thermoanalytical investigations 
The products were checked through thermogravimetry (TG and DTG), using a MOM 
instrument (MOM Ltd., Budapest, Hungary). The sample mass was 6 mg, and the heating rate 
was 5 °C/min in air atmosphere. Differential scanning calorimetry (DSC) with Perkin-Elmer 
DSC-2C (Perkin-Elmer Co., Norwalk, Connecticut, USA) and Mettler DSC 821® (Mettler-
Toledo GmbH, Switzerland) equipment provided additional information. The sample mass was 3 
to 4 mg, and the heating rate was 5 °C/min in an air atmosphere. The results were calculated 
from 3 measurements. 
Friability testing of the crystal agglomerates 
The samples were investigated with a Heberlein apparatus (Flisa, Le Locle, Switzerland). 
Five g of sieved sample (>0.32 mm) was put into the apparatus and 100 revolutions were 
performed. After this process, the fine particles were removed by sieving (>0.32 mm) and the 
percentage loss in mass was calculated. 
Study of flow properties: flow time, mass by volume, Carr index and rearrangement constant 
The flow time and the mass by volume were determined by the ASTM method (Ph. Eur. 
3). 
The Carr index was calculated from the poured and tapped densities [97]: 
tapped density - poured density 
Carr index (%) = — — 100 
tapped density 
For the determination of poured and tapped densities, a Stampfvolumeter 2003 (J. Engelsmann 
A. G. Apparatebau, Ludwigshafen, Germany) was used. Initially, 250 ml of substance was 
poured by hand into a measuring cylinder and the mass was determined by weighing. The poured 
density (minimum density) was calculated from the powder mass and the volume (250 ml). The 
cylinder was then tapped until the volume did not change (0-100 taps with 10 tap intervals ) and 
the volume was read again, giving the tapped density, and thus the maximum density possible. 
The Carr index reflects the compactibility of the crystals, and there is a correlation 
between the Carr index and the flowability of the crystals [66]. 
Stampfvolumeter measurements allow calculation of the rearrangement constant (k) [98]: 
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V - V 
V0 00 
where n is the number of taps, Vn is the initial volume of powder, Vn is the volume after n taps, 
and Vg is the final volume. 
After transformation of the equation, regression analysis was performed. The relationship 
between the variables can be described in terms of a linear model (y = 1+kn) or an exponential 
model (y = exp(l+kn)), where the slope of the curve is the rearrangement constant. If the 
constant is too small, the compression during tablet pressing can give rise to brittle fracture and 
plastic flow in certain regions before a close arrangement has been achieved in other regions. 
Compactibility and cohesiveness 
The Stampfvolumeter measurements allow calculation of the compactibility and 
cohesiveness via the modified Kawakita equation [99-100]: 
N 1 XT 1 
— = — N + — 
C a ab 
where N is the number of taps, C is the degree of volume reduction, and a and b are constants: a 
describes the degree of volume reduction at the limit of tapping and is called the compactibility; 
1/b is considered to be a constant related to cohesion and is called the cohesiveness. C is 
calculated via the following equation, and graphs of N/C vs. N are plotted: 
Vo 
The compactibility a and cohesiveness 1/b are obtained from the slope (1/a) and the intercept 
(1/ab) of the plot of the modified Kawakita equation. 
Study of plasticity and compressibility 
A Korsch EKO eccentric tablet machine (Emil Korsch Maschinenfabrik, Berlin, 
Germany) was applied for tablet making. The compression tools were single, flat punches 10 mm 
in diameter, furnished with strain gauges and a displacement transducer. The rate of compression 
2 0 
was 30 tablets/min with a pressure force of 17 kN, at an air temperature of 24 °C and a relative 
humidity of 45%. The tablets were pressed from the control and developed samples with 0.5% 
magnesium stearate as lubricant. The components were mixed for 5 min with a Turbula mixer 
(W. A. Bachofen Maschinenfabrik, Basel, Switzerland) at 50 rpm. During tablet pressing, the 
data were collected by computer. The energy parameters of 10 tablets were fixed for the 
calculation of plasticity and compressibility values. The measurements were repeated 3 times 
during the pressing. 
Plasticity (Pls-Af) w a s described by Stamm-Mathis: 
where if? is the effective work, which includes the useful work invested in deformation and the 
friction work. is the degree of elastic recovery during compression. E2 and E} can be 
calculated from the force - displacement curve. If the plasticity value is near 100, the material has 
a plastic character. 
Compressibility Prsmass\ was calculated via the following equation [58]: 
where crx is the tensile strength and WSpec is the specific work. WSpec expresses the effective 
work (if?) invested into the compression of unit mass of substance (m) at a given compression 
force. crx includes the crushing strength (if), the diameter (d) and the height (/i)of the 
comprimate [101]: 
2 H 
(T x n - d - h 
The crushing strength was investigated with a Heberlein apparatus (Flisa, Le Locle, 
Switzerland). The geometrical parameters of the tablets were measured with a screw micrometer 
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(Mitutoyo, Tokyo, Japan). The parameters of the tablets were determined after compression (24 
h) because of the texture change (elastic recovery). 
In fact, the compressibility (Prmass) includes the useful and the friction work, and also the 
hardness and the bulk density of the comprimate. This value can therefore provide more 
information on the behaviour of the materials than the plasticity or the crushing and the tensile 
strengths. 
Recording of diffuse -reflectance spectra 
Near-infrared spectroscopy furnishes useful information for the qualitative and 
quantitative analysis of materials without invasive sample preparation. It can be used to control 
the differences between the particle forms of the samples [102]. 
Diffuse reflectance was measured with a Hitachi (Japan) U-2501 UV/VIS/NIR 
spectrophotometer equipped with an integrating sphere (d=60 mm) and a PbS detector. The 
reflectance (R%) of samples was determined in the wavelength range 200-2500 nm, using a 5 
mm layered cell: 
R%=(Ir/IO)100 
where IR is the intensity of the diffusely reflected light collected by the integrating sphere and I0 
is the intensity of the incident light [103]. 
Determination of ASA and SA contents of the ASA samples 
The SA contents of the samples were controlled with a spectrophotometer (Spectromom, 
MOM, Budapest, Hungary); 0.250 g of sample was dissolved in 25 ml of ethanol (96%), and 
diluted with water up to 100 ml. After additional dilution (5 ml aliquot + 95 ml water), the 
absorbance was read at 297 nm for SA and at 276 nm for ASA. The testing was performed with a 
near-infrared spectroscope. 
Rate of dissolution ofASA samples 
The investigations were performed with the USP method (paddle). The medium was 
artifical gastric juice (pH=1.2) at 37±0.5 °C. The paddle speed was 50 rpm. The rate of 
dissolution of ASA from capsules was determined. The hard gelatine capsules (No. 0) were filled 
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with 100 mg of ASA crystals. The samples were analysed spectrophotometrically (Spectromom, 
MOM, Budapest, Hungary) at 276 nm. 
4.3. Tablet making and tablet investigations 
Production of ASA tablets 
The materials without any excipients were compressed into tablets by a Korsch EKO 
single punch tablet machine (Emil Korsch Maschinenfabrik, Berlin, Germany). The compression 
tools were single flat punches 10 mm in diameter. The rate of compression was 30 tablets/min 
with a pressure force of 18 kN, at an air temperature of 24 °C and a relative humidity of 30%. 
Formulation of chewable tablets containing Mgasp 
Five compositions were elaborated, in which Mgasp was the active agent. 20 mg of 
magnesium was planned for each tablet because of the daily repeated applicability and the needs 
of children. The polyols have a pleasant sweet taste, so the application of other corrigents was 
not necessary. 1% of magnesium stearate was used to promote lubrication. The composition of 
one tablet was as follows: 
Magnesium aspartate 250.0 mg 
Excipient (filler and binder material) 245.0 mg 
Magnesium stearate 5.0 mg 
Total mass: 500.0 mg 
Numbering according to excipients was as follows: 
Composition 1: Karion, 
Composition 2: Neosorb P 20/60, 
Composition 3: Xylisorb 700, 
Composition 4: Pearlitol SD 200, and 
Composition 5: Pearlitol 400 DC. 
The components were mixed for 5 min with a Turbula mixer (W. A. Bachofen 
Maschinenfabrik, Basel, Switzerland) at 50 rpm. The powder mixture was compressed into 
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tablets with a Korsch EKO eccentric tablet machine (Emil Korsch Maschinenfabrik, Berlin, 
Germany). The compression tools were single flat punches 12 mm in diameter. The rate of 
compression was 30 tablets/min with a pressure force of 18 kN, at an air temperature of 24 °C 
and a relative humidity of 45%. 
Investigation of tablets 
Investigations were carried out 24 h after pressing. Tablet mass was measured to an 
accuracy of 0.1 mg. The relative standard deviation (RSD) as mass variation was calculated from 
20 data points. The breaking hardness was determined through use of a Heberlein apparatus 
(Locle, Zurich, Switzerland) (20 tablets). The friability was determined with an Erweka 
friabilator (Erweka Apparatebau GmbH, Heusenstamm, Germany). 
The magnesium content of chewable Mgasp tablets was determined by atomic absorption 
spectrometry. The Pharmacopoeias (e.g. U.S. and European) usually prescribe the determination 
of magnesium by a titrimetric method. Atomic absorption spectrometry is more sensitive and 
more exact than titrimetry. The measurement of the solutions of excipients preceded the 
measurement of the chewable tablets. A small absorption in the case of magnesium stearate was 
measured at the applied wavelength and this was subtracted from the results. 
The measurements were carried out with a Perkin-Elmer 4100 (Bodenseewerk Perkin 
Elmer GmbH, Ueberlingen, Germany) atomic absorption spectrometer under the following 
conditions: flame-atomizing, wavelength 285.2 nm, slit width 0.7 nm, air - acetylene gas mixture 
(air: 8.01/min, acetylene: 3.5 1/min), read time 5 s. 
4.4. Statistical calculation 
The standard deviation (SD), relative standard deviation (RSD), the two-sample analysis 
and the regression analysis were carried out with the Statgraphics package (Copyright STSC, Inc. 
and Statistical Graphics Co., U.S.A.); the confidence limit was 95%. 
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5. RESULTS AND DISCUSSION 
5.1. Results on crystallization of ASA 
The ASA samples were developed by non-typical and typical spherical crystallization 
processes. The non-typical spherical crystallization technique (conventional stirred tank method) 
resulted in either monocrystals (ASA1) or non-spherical crystal agglomerates (ASA2). 
The developed ASA 1 crystals were tetragonal monocrystals with plane boundaries (Fig. 
6). A cooling rate of l°C/min resulted in the formation of a great number of seeds and did not act 
favourably either on the growth or the build-up of crystals. 
Fig. 6: Crystals of ASA1 developed by non-typical spherical crystallization 
Decrease of the cooling rate (0.5 °C/min) (ASA2) led to the appearance of a small 
number of crystal agglomerates besides the monocrystals (Fig. 7). Due to the slow cooling, the 
monocrystals were large and well-developed. The agglomerates were formed by the accidental 
encounter of 4-5 crystal seeds. Crystals built up at one point have a habit characteristic of 
monocrystals. 
Fig. 7: Crystals of ASA2 developed by non-typical spherical crystallization 
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Further decrease of the cooling rate and changes of the other parameters of crystallization 
did not bring about considerable changes in the formation of agglomerates. It may be noted that 
commercially available ASA products have a habit similar to that of the ASA1 and ASA2 
products. 
During the formation of ASA3, the crystals were transformed into spherical agglomerates 
(Fig.8). The process was typical spherical crystallization (agglomeration) with three solvents 
(ethanol - water - carbon tetrachloride). In the three-solvent system, the dissolved ASA was 
carried in the emulsion drops. Due to the effect of diffusion, the ethanol molecules left the 
emulsion drop and entered the aqueous phase through the emulsion film. The drop became 
oversaturated with respect to ASA, and in situ seed formation started at 37 °C (see Fig. 4), 
followed by crystal formation, which was also influenced by the cooling and mixing rates. In this 
process, therefore, it was not the accidental encounter of the crystals which resulted in the 
formation of crystal agglomerates. 
Fig. 8: Crystal agglomerates of AS A3 developed by typical spherical crystallization 
In fact, crystallization in emulsion drops was the case here, where the driving force was 
oversaturation caused by solvent diffusion. Although the built-up ASA crystals had the habit 
characteristic of monocrystals, the size of the agglomerate did not exceed the size of 
monocrystals and crystal agglomerates produced by non-typical spherical crystallization. ASA3 
agglomerates were open structures with very great hardness. Their friability, which is very 
important during further processing, was very favourable. The friability of the ASA3 sample was 
found to be 6.24±0.45%. For comparison, the maximum friability of granules is usually limited 
to 20% in pharmacopoeias. 
The length, breadth and roundness of the samples are detailed in Table 2. The different 
crystallization processes strongly influenced the habit of the crystals or crystal agglomerates. A 
faster cooling process resulted in very small crystals (ASA1) with an unfavorable roundness 
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value. Slower cooling helped the build-up of crystal agglomerates, but their number was low and 
the structure was only partly built-up (ASA2). Table 2 shows that ASA3 has the best roundness. 
Table 2: Particle size data on ASA samples 
Samples Length Breadth Roundness 
(pm) (pm) 
ASA1 Average 273.85 72.09 2.54 
SD 61.93 13.33 0.29 
Max. 367.91 95.73 3.28 
Min. 168.52 44.02 2.19 
ASA2 Average 667.94 314.69 1.72 
SD 173.36 96.74 0.25 
Max. 1200.00 747.69 2.38 
Min. 391.54 179.23 1.26 
ASA3 Average 521.72 332.01 1.40 
SD 143.16 98.65 0.13 
Max. 913.85 690.77 1.66 
Min. 300.31 136.61 1.15 
The micromorphology parameters reveal that the ASA2 and ASA3 samples have very 
low specific surfaces and micropore volumes. The larger average pore diameter of ASA3 is 
connected with the typical building of the spherical crystal particles (Table 3). The reduced 
specific surface involves a decrease in the electrostatic charge, which appears in the better 
compactibility and cohesivity properties of the samples. 
Table 3: Micromorphology properties of ASA crystals 
Specific surface 
(m2/g) 
Micropore volume* 
(10"3cm3/g) 
Average diameter of 
pores (nm) 
ASA1 0.11 0.14 7.31 
ASA2 0.06 0.08 8.32 
AS A3 0.04 0.04 32.26 
*Desorption micropore volumes were measured in the diameter range 1.7-300 nm 
The thermoanalytical investigations of the samples furnished the following results. The 
TG curves do not reveal any decrease in mass up to 133 °C. The samples have no adsorbed water 
or residual solvent on the surfaces of the crystals and crystal agglomerates. After the melting 
point (133-138 °C), the samples undergo decomposition with significant mass loss. The onset 
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temperature of the transition and the transition energy (AH,) of the samples show differences 
which can be ascribed to the crystallization process, but do not relate to the change in structure 
(Table 4). 
Table 4: DSC parameters of ASA samples 
Melting point 
(°C) 
Transition (onset) 
temp. (°C) 
AH, 
(J/g) 
ASA1 136.0 132.8 192.6 
ASA2 138.5 135.3 210.1 
AS A3 133.0 129.9 180.8 
Wavelength (nm) 
Fig. 9: Diffuse reflectance spectra of ASA samples 
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During the crystallization of ASA, the SA content of the samples can increase. This was 
checked by a near infrared method. The diffuse reflectance spectra of the ASA1 and ASA3 
samples in the wavelength range 200-350 nm were the same, which can be attributed to the 
uniform ASA content of the samples (Fig.9). 
In this range, only ASA2 exhibited a small peak for the SA as decomposition product. 
The amount of the SA determined spectrophotometrically was 1.02%. In the interval 350-2500 
nm, the ASA2 and ASA3 samples (with larger particle sizes and the best values of roundness) 
displayed smaller diffuse reflectances than that of ASA1 (with a smaller particle size and an 
unfavourable roundness value). 
As the rate of dissolution of the samples is basically influenced by the particle size, this 
was also checked. It is clearly shown in Fig. 10 that the rates of dissolution of the samples were 
almost the same, and only the ASA 1 crystals, which have a small particle size and consequently 
a large surface, underwent more rapid dissolution at the beginning of the examination. A very 
important fact to be pointed out is that the spherical crystal agglomerates of ASA3 did not exert 
an unfavourable influence on the dissolution rate. 
Time (min) 
—•—ASA1 
—O—ASA2 
—£—ASA3 
Fig. 10: Rates of dissolution of ASA samples 
The check on the technological parameters of the samples with respect to direct tablet 
making yielded the following results. The change in the habit of the crystals was reflected in the 
flowability of the samples. The spherical AS A3 had 'excellent' flow properties, as shown by the 
flow time and the Carr index (5-15%) (Table 5). The flow time of the prism-shaped monocrystals 
of ASA1 could not be determined with the Pharmatest apparatus because the substance did not 
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flow from the funnel of the apparatus. The Carr index of ASA1 was very high (19.99%). This 
means 'fair to passable' (18-21%) flow properties. 
Table 5: Powder rheological parameters of ASA samples 
Samples Flow time 
(s/100 ml) 
Poured density 
(g/ml) 
Tapped density 
(g/ml) 
Carr index 
(%) 
ASA1 no flow 0.3613 0.4517 19.99 
ASA2 12.1 0.3730 0.4025 7.33 
AS A3 8.4 0.4337 0.4613 5.99 
The data from the modified Kawakita equation can be seen in Table 6. The 
compactibilities (a) of ASA2 and ASA3 hardly differed; the compactibility of ASA1 was poorer. 
The cohesiveness (1/b) of AS A3 was outstanding, while those of the other two samples were 
higher and more disadvantageous. AS A3, which contained spherical crystals, had the best 
flowability, compactibility 
and cohesivity properties. ASA1, which did not form spherical agglomerates, gave the worst 
results. Hence, the transformation of commercial ASA crystals into spherical agglomerates led to 
improved flowability and compactibility. For ASA which did not undergo complete 
agglomeration, the investigation revealed worse technological parameters. 
Table 6: Compactibility (a) and cohesiveness (1/b) of ASA crystals by the Kawakita model 
Samples 1/ab 
intercept 
a 1/b r2 
ASA1 91.75 0.2519 23.10 0.9872 
ASA2 210.64 0.1017 21.42 0.9515 
ASA3 131.34 0.1047 13.76 0.9764 
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As the development of the ASA samples was carried out for the purpose of direct 
tabletting, the preformulation results to date were supplemented with tablettability studies. The 
samples were compressed to tablets without excipient and the physical parameters of the tablets 
were determined (Table 7). 
During the compression of the ASA1 crystals, the great friction was indicated by a 
powerful machine sound. The die cavity was filled unevenly due to the unfavourable habit of the 
crystals and their electrostatic charge. In consequence of this, a high degree of pressure force 
variation could be observed, which also influenced the other parameters, e.g. the deviation from 
the theoretical mass was high and the variation in mass exceeded 2%. 
The ASA2 sample, which has a greater particle size and is only partially spherical, 
exhibited better compressibility properties. The machine sound caused by friction became less 
intense, but the variation in mass of the tablet was still over 2%, which is related to the great 
cohesivity of the crystals. The latter can be attributed not only to the shape and size parameters of 
the crystals, but also to their surface properties. 
The results obtained with tablets compressed from ASA3 were in harmony with the flow 
properties, compactibility and cohesivity of the sample. At the same time, the importance of 
spherical crystallization was stressed for the purpose of the direct pressing of ASA crystals. 
There was no sign whatsoever of electrostatic charging during the pressing of AS A3. The crystal 
agglomerates can be compressed to tablets in an almost frictionless manner. This is confirmed by 
the slight variations in compression force, average mass and mass variation. The great hardness 
of the tablets and their small standard deviation also proved the important role of the ASA3 
sample. 
Table 7: Physical parameters of ASA tablets 
Materials Compression 
force 
(kN) 
Average 
height 
(mm) 
Average mass 
(g) 
Mass 
variation 
(RSD) 
(%) 
Breaking 
hardness 
(N) 
ASA1 10-15 2.8923 
(SD=0.0153) 
0.2757 2.5025 75.4 
(SD=3.5339) 
ASA2 10+1.5 3.0394 
(SD=0.060) 
0.2948 2.3258 66.8 
(SD=2.6998) 
AS A3 10±0.5 3.1323 
(SD=0.0427) 
0.3054 1.4833 71.4 
(SD= 1.6576) 
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The typical spherical crystallization process can be used successfully to manufacture 
spherical crystals of ASA with good flowability, compactibility and cohesivity. The ASA3 
crystallization process is optimized as concerns the form of the crystal agglomerates and the 
reproducibility of the product. On the basis of the results, this product can be recommended for 
direct tablet making. 
5.2. Results of crystallization of Mgasp 
For the Mgasp samples, the non-typical spherical crystallization resulted in crystal 
agglomerates with suitable technological parameters. 
The investigated Mgasp crystals and crystal agglomerates were found to have different 
particle sizes (Table 8). 
Table 8: Particle size distribution of Mgasp samples 
>400 
pm 
400-315 
pm 
315-250 
pm 
250-200 
pm 
200-100 
pm 
100-71 
pm 
<71 
pm 
Control - - - - 2.0 7.0 91.0 
Mgaspl - 2.4 3.3 5.1 39.5 17.8 31.9 
Mgasp2 14.5 11.9 35.9 16.5 17.7 2.3 1.2 
Mgasp3 3.6 5.6 13.0 15.9 41.1 10.0 10.8 
The control (commercial) Mgasp consists of single, very small crystals and agglomerated 
crystals with an unfavourable habit for direct compression (Fig. 11). The size of 91% of the 
crystals is less than 71 pm. The structure, surface, size and particle size distribution of the crystal 
agglomerates are determined by the parameters of the crystallization process. In the same way, 
Mgasp 1 and 2 were crystallized by salting-out combined with cooling, using the traditional 
mechanical stirring method. Mgasp 1 (Fig. 12) consists of smaller particles than those of Mgasp2 
(Fig. 13a) because of the slower initial cooling and the higher stirring rate. 
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Fig. 11: Control (commercial) Mgasp 
The spherical crystal agglomerates of Mgasp2 have a closed "cauliflower-like" structure 
with a relatively large particle size (62% of the particles larger than 250 pm) (Fig. 13b). In fact, a 
higher initial cooling rate and a lower stirring rate are very favourable in the building-up of 
crystal agglomerates with a closed structure. 
Fig. 12: Crystal agglomerates of Mgasp 1 
Fig. 13a: Crystal agglomerates of Mgasp2 Fig. 13b: Crystal agglomerates of Mgasp2 
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Fig. 14: Crystal agglomerates of Mgasp3 
The specific surfaces of the samples differ considerably; this is in keeping with their 
different particle sizes (Table 9). The micropore volumes of Mgaspl and Mgasp2 are the same, 
but the average diameter of the pores of Mgasp2 is significantly higher. 
Table 9: Micromorphology properties of Mgasp samples 
Specific surface 
(m2/g) 
Micropore volume* 
( lO'W/g) 
Average diameter 
of pores (nm) 
Control 0.76 2.80 13.5 
Mgaspl 0.63 2.51 10.4 
Mgasp2 0.42 2.83 27.3 
Mgasp3 0.46 1.41 12.8 
* Desorption micropore volumes were measured in the diameter range 1.7-300 nm in. 
The micromorphology properties of Mgaspl are nearest to the corresponding parameters 
of the control sample (Table 9). The particle size distribution of Mgasp3 (produced in a 
recirculation process) is between those of Mgaspl and Mgasp2. Agglomerates of Mgasp3 have a 
small specific surface, a small micropore volume and a small average pore diameter. (Figure 14, 
Table 9). 
The different macro- and micromorphologies of Mgaspl, 2 and 3 do not involve 
modification of the inner crystal structures of the agglomerates. This is documented by the 
results of thermoanalytical investigations. The TG curve does not reveal any decrease in mass up 
to 132 °C. The samples have no adsorbed water or residual solvent on the surfaces of the crystals 
or crystal agglomerates. All of the curves exhibit a step (132-189 °C) with a mass decrease of 
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about 20% (Table 10). The loss in mass relates to the elimination of 4 molecules of crystal water 
(20%). This and the melting of the crystals are accompanied by an endotherm in the DTA curve. 
The onset temperature of the transition, the melting point and the transition energy (AH,) are 
given in Table 11. The differences in the results can be ascribed to the crystallization process, but 
do not relate to the change in structure. 
Table 10: Thermogravimetric results on Mgasp samples 
TG step (°C) 
start end 
Mass decrease 
(%) 
Control 132.4 190.4 -19.1 
Mgaspl 131.9 189.0 -18.2 
Mgasp2 133.0 188.8 -19.7 
Mgasp3 133.5 189.7 -20.0 
Table 11: DSC parameters of Mgasp samples 
Melting point 
(°C) 
Transition (onset) 
temp. (°C) 
AHt 
(cal/g) 
Control 169.5 152.9 170.8 
Mgaspl 170.4 155.7 171.7 
Mgasp2 171.8 163.2 161.4 
Mgasp3 170.9 150.4 189.8 
The technological parameters such as the Carr index revealed that the flowability of the 
control product was "very poor" (Table 12), and the Takieddin rearrangement constant indicated 
a slow-packing character (Table 12). The spherical crystal agglomerates of Mgasp2, with a 
closed "cauliflower-like"structure, have "very good" flowability. The poured density is high, 
which is very important in the case of tablets with a large mass. The favourable particle form, 
size and surface result in fast rearrangement, with a very high rearrangement constant. Mgasp 1 
and 3 have "fair to passable" flow capacities with a slower rearrangement. 
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Table 12: Bulk densities, Carr indices and rearrangement constants of Mgasp samples 
Poured 
density 
(g/cm3) 
Tapped 
density 
(g/cm3) 
Carr index 
(%) 
Rearrangement 
constant (&) 
y=exp (1+kn) 
Control 0.51 0.82 37.61 0.038 
(r=0.9975) 
Mgaspl 0.43 0.58 26.41 0.155 
(r=0.9995) 
Mgasp2 0.61 0.64 5.32 0.389 
(r=0.9865) 
Mgasp3 0.40 0.49 18.71 0.290 
(r=0.9844) 
The compressibility parameters of the samples are collected in Table 13. The energy 
parameters {E2 and Es) determined on the basis of the force - displacement curves indicate 
approximately the same plasticity values for the samples. It is very important that the 
deformability of the samples (Pls_M ) is not influenced by the crystallization parameters. 
Therefore, the internal crystal structure of the spherical agglomerates does not change; only the 
external morphology (size, form, surface, etc.) is affected. The same result was documented by 
the thermoanalytical investigations. 
Table 13: Compressibility parameters of Mgasp (pressure force: 17 kN) 
(space filling of the die cavity of tablet machine: 864 mm3) 
Mass of 
tablet 
(g) 
Mass 
variation 
(RSD) 
(%) 
P^SM 
(%) 
Tensile 
strength 
(MPa) 
Pr 
* mass 
(Pa/J kg1) 
Control 0.394 5.2 92.3 
(SD=1.49) 
0.13 
(SD=0.10) 
13.5 
(SD=7.81) 
Mgaspl 0.475 0.7 89.9 
(SD=0.85) 
0.75 
(SD=0.03) 
26.3 
(SD=0.86) 
Mgasp2 0.639 0.8 93.3 
(SD=1.03) 
0.58 
(SD=0.03) 
20.5 
(SD=0.57) 
Mgasp3 0.484 0.8 90.2 
(SD=0.81) 
0.67 
(SD=0.02) 
22.3 
(SD-0.46) 
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The tablets containing the spherical crystal agglomerates and the control sample differ 
considerably in the mass of tablet, mass variation (RSD) and tensile strength. 
The tablet compression was carried out by maximal space filling of the die cavity of the 
tablet machine. The difference in the mass of tablet could be explained by the bulk density and 
the arrangement of the samples in the die cavity. This is reflected by the compressibility values 
(Prmass) too. The compressibilities of the spherical crystal agglomerates (Mgaspl, 2 and 3) are 
better than that of the control product (Table 13). The greater tensile strength and the 
compressibility value of the tablet containing Mgaspl can be explained in terms of enhanced 
binding connected with the small particle size. 
Both the traditional mechanical stirring crystallization and the recirculation process are 
suitable for the development of spherical crystal agglomerates of Mgasp. Mgaspl, 2 and 3 have 
very good flowability and compressibility, in contrast with the commercial (control) sample. 
According to the parameters of the tablets (mass, tensile strength, etc.) Mgaspl, 2 and 3 can be 
used for direct tablet making. However, primarily Mgasp2 can be suggested for the production of 
tablets with a high active agent content. 
5.3. Development of chewable tablets containing Mgasp 
The active drug for direct tablet making was produced by a manufacturing process (on a 
pilot scale) as a result of crystallization process development. The manufactured Mgasp had the 
same preformulation parameters (flowability, compressibility, etc.) as those of the products 
developed on a laboratory scale. During the development of the chewable tablet-composition the 
particle size distribution of the Mgasp and the excipients was the subject of the first 
preformulating investigation. The investigated materials were found to have different particle 
sizes (Figs 15a and 15b). 
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The particles were more or less spherical in form. 90% of the Mgasp crystals were 
smaller than 400 pm. Pearlitol SD 200 had a similar particle size. 90% of the crystals of Pearlitol 
400 DC ranged between 200 and 630 pm, but Xylisorb, Neosorb and Karion consisted of much 
larger crystals (particularly Neosorb and Karion). Thus, the particle size of Pearlitol SD 200 was 
the most similar to that of Mgasp, and those of Neosorb and Karion were the most different. 
The results of the determination of mass by volume are presented in Table 14. It can be 
seen that the mass by volume of Xylisorb (73.36 g/100 ml) corresponded most closely to that of 
Mgasp (78.97 g/100 ml), and that of Karion was the most different, with approximately half the 
mass by volume of the active agent. 
The similar particle size distribution and mass by volume ensure the homogeneous distribution 
of the active agent in the powder mixture and help prevent the separation of particles with 
different sizes in the tablet making. Therefore, these properties influence the constancy of the 
active agent content (uniformity of content) in the chewable tablets. 
The results of Carr index determination of are given in Table 14. The connection between 
the Carr index and flowability reveals that the applied materials had excellent flow properties 
(Carr index = 5-15%); this was particularly true for Neosorb, Pearlitol 400 DC and Pearlitol SD 
200, due to their crystal habit (form and surface). The preformulation results allow Neosorb P 
20/60 and two sorts of Pearlitol to be suggested as filler and binder materials for direct tablet 
making. 
Table 14: Masses by volume and Carr indices of the applied materials 
Materials Mass by volume Carr index 
(g/100 ml) (%) 
Magnesium aspartate 78.97 9.07 
Karion 37.25 13.60 
Neosorb P 20/60 59.37 4.27 
Xylisorb 700 73.36 13.10 
Pearlitol SD 200 44.93 8.53 
Pearlitol 400 DC 64.67 5.60 
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During the compression process, there were no problems except in the case of the mixture 
containing Xylisorb, because the filling depth was very low (4 mm) due to the large mass by 
volume, and this caused problems in filling and compression. These problems are reflected in the 
physical properties of Xylisorb tablets. The physical parameters of the chewable tablets are listed 
in Table 15. 
In respect of mass, mass variation, friability and breaking hardness, the tablets proved of good 
quality, except those of Xylisorb. Tablets containing Karion exhibited the best hardness, whereas 
those of Pearlitol 400 DC displayed a very low hardness. 
Table 15: Physical parameters of chewable tablets 
Composition of Filling Average Mass Friability Breaking 
chewable tablets depth mass variation hardness 
(mm) (g) (RSD) (%) (N) 
Composition 1 6 0.5275 0.65 0.92 105.8 
(Karion) (SD=0.03) (SD=13.14) 
Composition 2 5 0.5117 0.33 1.16 66.0 
(Neosorb) (SD=0.07) (SD=7.11) 
Composition 3 4 0.4561 6.65 the tablets not 
(Xylisorb) broke measurable 
Composition 4 6 0.5035 0.18 1.20 77.9 
(Pearlitol SD 200) (SD=0.06) (SD=4.18) 
Composition 5 5 0.5031 0.24 1.62 46.9 
(Pearlitol 400 DC) (SD=0.09) (SD=2.79) 
The results of analytical investigations are to be seen in Table 16. For a tablet of 0.50 g, 
the theoretically measurable magnesium content is 19.72 mg and Table 16 shows the deviations 
from this theoretical value. The results on the tablets containing Karion indicate deviations in 
excess of the value set by the U.S. Pharmacopeia (±10%). In this case, the tablet mass, mass 
4 1 
variation and hardness were suitable, and the uniformity of mass (presuming homogeneity of the 
powder mixture) suggests the uniformity of the active agent content. However, there was a great 
difference between the particle size and the mass by volume of Karion and those of Mgasp, so 
that the particles of the powder mixture separated during the tabletting process. In consequence 
of this, the active agent content of Karion tablets was not suitable. 
The magnesium content in the Xylisorb tablets was good, because of the similar mass by 
volume to that of Mgasp, but the physical parameters of these tablets were not suitable (filling 
depth). Other compositions did not exhibit large differences from the theoretical value. 
Table 16: Results of analytical investigation of chewable tablets 
Composition of Tablet mass Magnesium Deviation of 
chewable tablets (g) content magnesium content 
(mg) from the theoretical 
value (mg) 
0.5113 20.17 0.45 
Composition 1 0.4838 17.70* -2.02* 
(Karion) 0.5399 24.33* 4.61* 
0.5300 21.80* 2.81* 
0.5074 19.72 0.00 
0.4937 20.17 0.45 
Composition 2 0.5037 19.72 0.00 
(Neosorb) 0.4975 20.79 1.07 
0.4996 20.56 0.84 
0.5146 19.72 0.00 
0.4822 19.10 -0.62 
Composition 3 0.4603 18.43 -1.29 
(Xylisorb) 0.4512 17.93 -1.79 
0.4840 19.16 -0.56 
0.4805 19.21 -0.51 
0.4908 20.28 0.56 
Composition 4 0.4785 19.72 0.00 
(Pearlitol SD 200) 0.5078 20.96 1.24 
0.4937 20.00 0.28 
0.5085 20.34 0.62 
0.4910 20.17 0.45 
Composition 5 0.4905 20.84 1.12 
(Pearlitol 400 DC) 0.4916 21.18 1.46 
0.4941 20.73 1.01 
0.5030 21.35 1.63 
These values lie outside the range of the magnesium content: 17.75-21.69 mg 
(theoretical value: 19.72 mg) 
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These investigations established that two of the applied vehicles (Pearlitol SD 200 and 
Neosorb) are suitable in all respects (physical parameters and analytical investigation) for direct 
compression and the formulation of chewable tablets with these compositions. These polyols 
display better flow, a similar particle size distribution (Pearlitol SD 200) and a similar mass by 
volume (Neosorb) to those of Mgasp. Pearlitol 400 DC, Xylisorb and Karion have different 
particle size distributions and masses by volume from those of the active agent, and in these cases 
the physical parameters or the magnesium content were not suitable. These problems can 
probably be eliminated by modification of the composition. 
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6. SUMMARY 
Direct compression is the most efficient process used in tablet manufacturing because it is 
the fastest, simplest, and least expensive tablet-compression procedure. However, although this 
technique seems quite simple, it requires that different properties of drug materials (free flow and 
plastic behaviour) should be manifested simultaneously. Many drugs do not exhibit these 
properties: they have poor flowability and compressibility. 
One of the possible solutions may be the spherical agglomeration of drug crystals by 
spherical crystallization. This possibility recently came into the forefront of interest because the 
habit of the particles (form, size, particle size distribution, surface, etc.) can be changed by the 
crystallization process. The spherical crystallization (agglomeration) technique has recently 
received great attention and gained considerable importance in the pharmaceutical field. The 
particle diameter of drug materials produced by spherical crystallization is about 300-500 pm 
and their form is more or less spherical. The agglomerates exhibit very good flow, high bulk 
density and high compressibility. 
The present research work relates to the improvement of the pharmaceutical 
technological parameters of drug materials via the spherical crystallization process, the quality 
of the products and the formulation of chewable tablets with developed active agent. 
On the basis of the results of the present research work, the most important findings are 
as follows: 
•=!> Many active drugs have poor technological properties, e.g. particle size distribution, 
flowability and compressibility, and they are therefore not suitable for direct tabletting. Such 
materials include acetylsalicylic acid (ASA) and magnesium aspartate (Mgasp). Spherical crystal 
agglomeration was used to solve this problem. A non-typical spherical crystallization process 
was applied in the case of magnesium aspartate (salting-out combined with cooling for Mgasp 1 
and Mgasp2, and a recirculation process for Mgasp3), and a typical (ASA3) or a non-typical 
spherical agglomeration (ASA1 and ASA2) technique in the case of acetylsalicylic acid. 
4 4 
•4) Quality control of the products was carried out from various aspects: determination of 
micro- and macromorphological parameters, recording of diffuse reflectance spectra, 
thermoanalytical investigations, atomic absorption analysis, and investigation of other 
technological properties (flowability and compressibility). In the case of magnesium aspartate, 
all three products have a spherical form (especially Mgasp3) and better technological properties 
than the commercial (control) material (especially Mgasp2 and Mgasp3). In the case of 
acetylsalicylic acid, AS A3 has the most spherical form and the best technological results; ASA1 
has seed-form crystals and poorer attributes. 
The spherical agglomeration technique resulted in crystals with good properties (Mgasp2, 
Mgasp 3 and ASA3) and successfully produced materials suitable for direct tablet making. 
=J> Chewable tablets containing magnesium aspartate were developed with the use of 
different polyols (Instant Karion, Neosorb P 20/60, Xylisorb 700, Pearlitol SD 200 and Pearlitol 
400 DC). The tablets were made from five compositions by direct pressing. After compression, 
they were investigated. The results indicated that two of the applied vehicles (Pearlitol SD 200 
and Neosorb) are suitable in all respects for direct compression in these compositions. In the 
other cases, modification of the compositions can probably eliminate the problems. 
The new relations of the present work are as follows: 
•^Successful spherical crystallization of magnesium aspartate and acetylsalicylic acid. 
•^Suggestion to the experts of crystallization relating to the quality control of the products. 
•^Determination of magnesium contrary to Ph. Eur. 4. 
•=!>Quality control of polyols in connection with the formulation of chewable tablets. 
This work was supported by the Hungarian National Research Foundation (OTKA T023029 and 
T032707). 
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